SNMMI Update: Appropriate Use Criteria (AUC) and Quality Payment Program (MIPS)

Mid-Eastern Chapter of the Society of Nuclear Medicine 48th Annual Spring Meeting The HOTEL at Arundel Preserve in Hanover, MD April 13-15, 2018

> Sukhjeet Ahuja, MD, MPH Director, Evidence and Quality SNMMI sahuja@snmmi.org



Overview

- AUC Background (PAMA Legislation 2014)
- Q-PLE (Requirements and List)
- Q-CDSM (Requirements and List)
- MPFS Update PAMA/AUC
- Update on MACRA/MIPS/QPP
- Update on AHCA, BCRA and ACA (Tax Reform Act 2017)
- Known Unknowns for PAMA and QPP
- Unknown Unknowns for PAMA and QPP



AUC Background

Protecting Access to Medicare Act of 2014



Protecting Access to Medicare Act (PAMA) 2014

- On March 31, 2014, Congress passed the "Protecting Access to Medicare Act of 2014" (H.R. 4302)
 - Tied advanced diagnostics imaging services physician reimbursement to appropriate use criteria (AUC).
 - Ordering professionals (OP) will have to consult AUCs via a clinical decision support mechanism prior to ordering ADIS, for help in determining whether an exam is clinically appropriate for a patient's condition
 - Advanced Diagnostic Imaging Services are defined as diagnostic magnetic resonance imaging, computed tomography, nuclear medicine (including positron emission tomography), and other diagnostic imaging services specified by the Secretary in consultation with physician specialty organizations and other stakeholders



What are Appropriate Use Criteria (AUC)?



Objective:

Identify patients who will most appropriately benefit from a procedure, thus resulting in a more effective and equitable allocation of healthcare resources.



Objective:

Identify patients who will most appropriately benefit from a procedure, thus resulting in a more effective and equitable allocation of healthcare resources. Must be created or endorsed by national medical specialty society or other organization that is a Qualified provider-led entities (Q-PLE)



Objective:

Identify patients who will most appropriately benefit from a procedure, thus resulting in a more effective and equitable allocation of healthcare resources. Must be created or endorsed by national medical specialty society or other organization that is a Qualified provider-led entities (Q-PLE)

Must have stakeholder consensus



Objective:

Identify patients who will most appropriately benefit from a procedure, thus resulting in a more effective and equitable allocation of healthcare resources. Must be created or endorsed by national medical specialty society or other organization that is a Qualified provider-led entities (Q-PLE)

Must have stakeholder consensus

Be scientifically valid & evidence-based



Objective:

Identify patients who will most appropriately benefit from a procedure, thus resulting in a more effective and equitable allocation of healthcare resources. Must be created or endorsed by national medical specialty society or other organization that is a Qualified provider-led entities (Q-PLE)

Must have stakeholder consensus

Be scientifically valid & evidence-based

Be based on publicly available studies that are published and reviewable by stakeholders



SNMMI AUC Development Project

- SNMMI modeled its AUC development process after the RAND/UCLA criteria and includes a systematic review of evidence followed by development of AUC for various common clinical scenarios using a modified Delphi approach
- This process is also consistent with the Institute of Medicine's standards for developing trustworthy clinical guidance documents
- The process included identification of relevant clinical scenarios, a systematic synthesis of available evidence, individual and group ratings of the scenarios suing a formal consensus process, and drafting the final AUC document based on the group ratings and discussions
- To conduct independent and objective systematic review of the evidence, SNMMI has an ongoing contract with the Oregon Health and Science University's Evidence-based Practice center
- The primary purpose of these systematic reviews is to assess the diagnostic accuracy and comparative effectiveness of selected nuclear medicine procedures in clinical decision making and patient outcomes

Specialty Societies/Organizations Collaborating with SNMMI

- Alzheimer's Association
- European Association of Nuclear Medicine
- American Society of Clinical Oncology
- American College of Emergency Physicians
- American College of Radiology
- American Society of Hematology
- Society of Thoracic Surgeons
- American College of Chest Physicians
- American Gastroenterological Association
- American College of Nuclear Medicine
- Society for Pediatric Radiology
- Canadian Association of Nuclear Medicine
- North American Neuroendocrine Tumor Society
- Endocrine Society
- Society of Surgical Oncology
- National Comprehensive Cancer Network
- American College of Physicians
- World Conference on Interventional Oncology
- Radiological Society of North America
- Association of University Radiologists
- American Roentgen Ray Society
- American Neurogastroenterology and Motility Society
- American Board of Nuclear Medicine
- Canadian Cardiovascular Society

- Society of Cardiovascular Computed Tomography
- American College of Cardiology
- American Society for Radiation Oncology
- European Neuroendocrine Tumor Society
- World Molecular Imaging Society
- American Urological Association
- American Academy of Family Physicians
- American Thyroid Association
- American Head and Neck Society
- American Association of Clinical Endocrinology




Multidisciplinary Expert Panel Reports COI

AND MOLECULAR IMAGING


SNM SOCIETY OF NUCLEAR MEDICINE






AND MOLECULAR IMAGING

SNM SOCIETY OF NUCLEAR MEDICINE




S NM SOCIETY OF



S NM SOCIETY OF

Rating the Indications




May Be Appropriate (Score 4-6): The use of the procedure is uncertain for the specific indication, although its use may be appropriate and acceptable. Uncertainty

SNM


implies that more research is needed to classify the indication definitively.

Rarely Appropriate (Score 1-3): Use of the procedure is inappropriate for the specific indication and generally is not considered acceptable.



SNM SOCIETY OF NUCLEAR MEDICINE

AND MOLECULAR IMAGING



S NM SOCIETY OF

NUCLEAR MEDICINE D MOLECULAR IMAGING

> Each AUC Committee will go through each of these steps to complete the needed development process

If cost and quality outcomes data are available, the evidence will be reviewed and considered. Otherwise, this step is skipped.



AUC Development – Steps

- Identify AUC Topic & Chair

- Multidisciplinary AUC Workgroup – Members Selection



- AUC Workgroup Conflict of Interests Submission
- SNMMI Conflicts of Interests Adjudication



- Workgroup: Introduction and kickoff call
- Workgroup Develop PICO search parameters



- OHSU Overview of systematic review results to workgroup

- Workgroup finalize draft clinical indications

Workgroup: Verify Key Clinical Questions developed by OHSU
OHSU Provides training for Evidence grading and scoring, "GRADE training"

- Contract with OHSU to conduct Systematic Literature Review - Identify clinical indications

- Workgroup Frist round evidence scoring adjudication
- Workgroup second/third round scoring adjudication

- Workgroup writing assignments

- Workgroup: Draft document



- SNMMI: Identify & recruit peer reviewers
- Peer Reviewers: Review document & provide feedback


- SNMMI: Submit document for board approval



AUC Development – Steps

The Strength of Evidence - Evidence Ladder/Hierarchy

- Meta analyses
- High quality systematic reviews
- Large randomized trials with clear results
- Small randomized trials with uncertain results (i.e., positive trends without statistical significance)
- Nonrandomized trials with contemporary controls
- Nonrandomized trials with historical controls
- Cohort studies
- Case control studies
- Case series
- Expert opinions, Editorials, Ideas





Appropriate Use Criteria - Issues

How to determine the topics for AUCs? Background and Rationale

SNMMI Prioritization of AUC Topics

• Prioritize

SNN

- highest volume Nuclear Medicine Procedures based on the CMS data
- Conduct an environmental scan
 of existing clinical guidelines and AUCs (developed)
 - of existing clinical guidelines and AUCs (developed by other organizations)
- List high volume Nuclear Medicine Procedures lacking appropriate AUCs

- (where NM is at a disadvantage and/or the AUCs are not evidence-based)

SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Highest Volume Nuclear Medicine Studies According to CMS

Modality	Highest Volume Nuclear Exams (CMS)	
Nuclear Medicine (14.08 MM)	Myocardial Ischemia Perfusion (9.97 MM)	
	Bone Scans (2.12 MM)	Prostate Ca
		Breast Ca
		Back Pain – unspecified
	Liver/Hepatobiliary (1.17 MM)	
	Respiratory (0.82 MM)	
PET/CT (1.5 MM)	Lung Nodule (malignant neoplasm) – (Solitary pulmonary nodule tops list)	
	Breast Ca	
	ENT related	
	Lymphatic	
	Colon	



Qualified Provider Led-Entities

- CMS proposed a new process for AUC Development
- Organization developing AUC must <u>follow an evidence-based process as specified by</u> <u>CMS, document that process</u>, and <u>apply to CMS</u> to get certified as an "Approved" or "Qualified" Provider-led Entity (Q-PLE). The duration of qualification is 5 years.
- The application to CMS must be made by December 31 (SNMMI applied December 2015 and was approved June 2016)
- CMS publishes a list of "Approved" or "Qualified" Provider-led Entities by June 30 of the following year
- SNMMI is one of the only 3 specialty societies that was approved as a PLE, along with ACR and ACC
- Instead of reviewing individual AUC, all the documents produced by these "Approved" or "Qualified" provider led entities will be considered "deemed" or "approved"
- CMS has postponed the implementation date for the start of the AUC program to <u>January</u> <u>1, 2020</u> under the MPFS 2018



List of Approved or Qualified-PLEs as of June 2017

•American College of Cardiology Foundation

American College of Radiology

•Banner University Medical Group-Tucson University of Arizona*

•CDI Quality Institute

- Cedars-Sinai Health System*
- Intermountain Healthcare

•Massachusetts General Hospital, Department of Radiology

Medical Guidelines Institute*

•Memorial Sloan Kettering Cancer Center* •National Comprehensive Cancer Network

•Sage Evidence-based Medicine & Practice Institute*

•Society for Nuclear Medicine and Molecular Imaging

•University of California Medical Campuses

University of Utah Health*

•University of Washington School of Medicine

•Virginia Mason Medical Center*

•Weill Cornell Medicine Physicians Organization

SNM SOCIETY OF MIL AND MOLECULAR IMAGING

SNMMI AUC Published/Under Development/Topics Identified

SNMMI AUC Published Till Date

- Amyloid Imaging AUC
- Bone Scintigraphy in Breast and Prostate Cancer
- Hepatobiliary Scintigraphy in Abdominal Pain
- Ventilation Perfusion Imaging in Pulmonary Embolism
- PET CT for Restaging and Treatment Response Evaluation in Malignancies
- Somatostatin Imaging for Neuroendocrine Tumors

SNMMI AUC Under Development

- PET Myocardial Perfusion Imaging
- Infection Imaging
- Gastrointestinal Transit
- Prostate Cancer Imaging
- Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer (DTC)

New Topics for AUC

- Lymphoscintigraphy
- Ra-223
- Benign Tumors of Thyroid
- Brain Imaging (HMPAO and DAT)
- Renal Imaging

Collaborating Organizations: AUC Under Development

- American Association of Clinical Endocrinologists (AACE)
- American Academy of Family Physicians (AAFP)
- American College of Cardiology (ACC)
- American College of Nuclear Medicine (ACNM)
- American College of Physicians (ACP)
- American Gastroenterological Society (AGA)
- American Head and Neck Society (AHNS)
- American Society of Clinical Oncology (ASCO)
- American Society of Nuclear Cardiology (ASNC)
- American Society for Radiation Oncology (ASTRO)
- American Thyroid Association (ATA)
- American Urological Association (AUA)
- Canadian Cardiovascular Society (CCS)
- Canadian Nuclear Safety Commission (CNSC)
- Endocrine Society

S NM SOCIETY OF

European Association of Nuclear Medicine (EANM)

PET-MPI AUC Workgroup Members

Thomas Schindler, MD* (SNMMI)

Robert Gropler, MD (SNMMI)

Timothy Bateman, MD (SNMMI)

Rob Beanlands, MD, FRCPC, FACC (ASNC, ACC, CCS, SNMMI)

Warren Laskey, MD, MPH

Venkatesh Murthy, MD, PhD (SNMMI)

Daniel Berman, MD (ACC, SCCT, SNMMI)

Terrence Ruddy, MD, FRCPC, FACC (CCS, CSNC, SNMMI)

Panithaya Chareonthaitawee, MD (ASNC, SNMMI)

Lorraine De Blanche, MD (ACNM)

Marcelo Di Carli, MD (SNMMI)

Vasken Dilsizian, MD (ASNC, SNMMI)

Sharmila Dorbala, MD, MPH (SNMMI)


Leslee Shaw, PhD (ACC, SCCT)

Prem Soman, MD, PhD, FRCP(UK), FACC (AAC, AANC, SNMMI)

David Winchester, MD (ACP)

Hein Verberne, MD, PhD (EANM)

PET-Myocardial Perfusion Imaging (MPI) AUC Process



Infection Imaging AUC Workgroup Members

Chris Palestro, MD* (SNMMI)

Alicia Clark, MD

Erin Grady, MD, FACNM (ACNM, SNMMI)

Sherif Heiba, MD (SNMMI)

Ora Israel, MD (SNMMI)

Alan Klitzke, MD (ACNM, SNMMI)


Charito Love, MD (ABNM, RSNA, SNMMI)

Mike Sathekge, MD, PhD (SNMMI)

Chun Kim, MD (SNMMI)

Ted Treves, MD (SNMMI)

Tracy Yarbrough, MD, PhD (ACNM, SNMMI)



Gastrointestinal Transit - Workgroup Members

Alan Maurer, MD* (SNMMI)

Thomas Abell, MD (AGA)

Paige Bennett, MD (SNMMI)

Jesus Diaz, MD (ACR, AUR, ARRS, RSNA, SNMMI)

Lucinda Harris, MD (ACP)

William Hasler, MD (AGA)

Andrei Iagaru, MD, FACNM (SNMMI)

Kenneth Koch, MD (AGA)


Richard McCallum, MD (ANMS)

Henry Parkman, MD (ANMS)

Satish Rao, MD (ANMS, AGA)

Mark Tulchinsky, MD, FACNM, CCD (ACNM, SNMMI)

Gastrointestinal Transit AUC Process



Prostate Cancer Imaging AUC Workgroup Members

Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI* (USC; SNMMI)

Leslie Ballas, MD (USC; ASTRO)

Peter Choyke, MD, FACR (NCI; ASCO, SNMMI)

Stefano Fanti, MD (University of Bologna; EANM)

James Gulley, MD, PhD, FACP (NCI; ACP)

Ken Herrmann, MD (Universitätsklinikum Essen; EANM, ENETS)

Thomas Hope, MD (USC; SNMMI)

Alan Klitzke, MD (Roswell Park Cancer Institute; ACNM, SNMMI)

Jorge Oldan, MD (UNC, Chapel Hill; ASCO, SNMMI)


Martin Pomper, MD, PhD (Johns Hopkins Medical School; SNMMI)

Rathan Subramaniam, MD, PhD, MPH, FACNM (UT Southwestern Medical Center; ACNM, SNMMI)

Samir Taneja, MD (NYU Longone Medical Center; AUA)

Hebert Alberto Vargas, MD (Memorial Sloan Kettering Cancer Center; ASCO)

Prostate Cancer Imaging AUC Process



Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer AUC Workgroup Members

Kevin Donohoe, MD* (SNMMI)

Jennifer Aloff, MD, FAAFP (AAFP)

Anca Avram, MD, FACNM (ACNM, SNMMI)

KG Bennet, MD (ACNM, SNMMI)

Erica Cohen, DO, MPH, CCD (ACNM, SNMMI)

Luca Giovanella, MD, PhD (EANM)

Bennett Greenspan, MD, FACNM, FACR (SNMMI)

Seza Gulec, MD

Aamna Hassan, MD

Richard Kloos, MD (ATA)

Carmen Solórzano, MD, FACS (AAES)

Brendan Stack, MD (AHNS)


Mark Tulchinsky, MD, FACNM, CCD (SNMMI)

Michael Tuttle, MD (AACE)


Douglas Van Nostrand, MD, FACP, FACNM (SNMMI)

Jason Wexler, MD (Endocrine Society)

Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer AUC Process



Delivery of AUCs – Clinical Decision Support (CDS) tool(s).



Delivery of AUC – Clinical Decision Support (CDS) Mechanism

SNM SOCIETY OF NUCLEAR MEDICINE

- "Protecting Access to Medicare Act of 2014" (H.R. 4302)
 - Directs the Secretary of HHS to launch (by 2017) a program that encourages the use of appropriate use criteria for advanced diagnostic imaging services (ADIS)
 - Ordering professionals (OP) will have to <u>consult AUCs via a clinical</u> <u>decision support mechanism prior to ordering ADIS</u>, for help in determining whether an exam is clinically appropriate for a patient's condition
 - In addition to the private sector clinical decision support mechanism, a clinical decision support mechanism to be established by HHS
 - It could be an existing clinical decision support tool of another organization or could be created de novo by HHS
 - CMS/HHS has not stated what this clinical decision support tool would look like or whether CMS will in fact create one in the future

Delivery of AUC – Clinical Decision Support (CDS) Mechanism

S NM SOCIETY OF NUCLEAR MEDICINE

- Requirements for the Clinical Decision Support Mechanism
 - The mechanism determines the <u>extent to which an applicable</u> <u>imaging service ordered is consistent with the applicable</u> AUC
 - The mechanism generates and provides to the ordering professional a certification or documentation that documents that the qualified clinical decision support mechanism was consulted by the ordering professional
 - In the case where there is more than one applicable AUC for an applicable imaging service, the <u>mechanism indicates the criteria</u> that it uses for the service
 - The mechanism is <u>updated on a timely basis</u> to reflect revisions to the specification of applicable appropriate use criteria
 - The mechanism performs other functions such as a requirement to provide aggregate feedback to the ordering professional



Qualified Clinical Decision Support (CDS) Mechanism – November 2017

- AIM Specialty Health ProviderPortal®*
- Applied Pathways CURION™ Platform
- Cranberry Peak ezCDS
- eviCore healthcare's Clinical Decision Support Mechanism
- Medicalis Clinical Decision Support Mechanism
- National Decision Support Company CareSelect[™]* (Acquired by Change Healthcare in January 2018)
- National Imaging Associates RadMD
- Sage Health Management Solutions Inc. RadWise®
- Test Appropriate CDSM

*Free Tool Available



Clinical Decision Support Mechanisms with Preliminary Qualification -November 2017

- Cerner CDS mechanism
- Evinance Decision Support
- Flying Aces Speed of Care Decision Support
- LogicNets' Decision Engines
- MedCurrent OrderWise™
- Reliant Medical Group CDSM
- Stanson Health's CDSM

Free CDS Mechanism as mandated by PAMA

 Not enough clarity on "Free CDS Mechanism" that will be offered, if at all, by CMS as required by PAMA legislation



SNMMI Collaboration with CDSMs

National Decision Support Company



stanson <> health



A Siemens Healthineers Company

SNM SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

SNMMI AUC Licensing Agreement with CDSMs

- SNMMI has contracted with NDSC and Stanson Health to host nuclear medicine AUC developed by the society under a licensing agreement.
- Currently working with these CDSMs to convert AUC recommendations into electronic format and incorporate into the EHRs.
- Exploring collaboration with Medicalis (Siemens Healthineers), Logic Nets and Infinix.

CDSM – Driving Quality Improvement (Source NDSC)

The Order Appropriateness Report provides an overview of an organization's order scoring breakdown (green, yellow, red, and no score). It includes the percentage and the number of orders that fall into each score range.

S NM SOCIETY OF

NUCLEAR MEDICINE

Last Six Months - Appropriateness by Modality / 09/01/2015 to 02/29/2016 grouped by Modality Edit Totals - 81,910 Orders 1,555 58.012 9.488 12.855 70.82% 1.90% 15.69% 11.58% Appropriate [7-9] May Be Appropriate [4-6] Not Appropriate [1-3] No Score Order (%) Appropriateness Appropriate [7-9] 58.012 (70.82%) 12.855 (15.69%) [7-9] Not Appropriate [1-3] 9.488 (11.58%) No Score 1,555 (1.90%) 58,012 Total Orders 81,910 Modality Details 60.000 45 000 30.000 15,000 47 5 3 \$


Order Appropriateness Report

CDSM – Driving Quality Improvement (Source NDSC)

The CDS Impact Report shows the total number of orders and the number of times the decision support window was shown to the end user. Within the subset where feedback was shown, the report then shows the percentage of orders where the provider changed to a new exam, cancelled the exam, or proceeded with the original order.

SNM

SOCIETY OF NUCLEAR MEDICINE



CDS Impact Report

Authorizing Provider	Total Exams	Changed (%)	Proceeded (%)	Canceled (%)
O Provider 2325	74	14 (18.92%)	49 (66.22%)	11 (14.86%)
O Provider 2339	73	17 (23.29%)	48 (65.75%)	8 (10.96%)
O Provider 2311	71	17 (23.94%)	46 (64.79%)	8 (11.27%)
O Provider 2331	66	16 (24.24%)	42 (63.64%)	8 (12.12%)
O Provider 2303	66	7 (10.61%)	50 (75.76%)	9 (13.64%)
O Provider 2341	66	13 (19.70%)	43 (65.15%)	10 (15.15%)
O Provider 2343	66	14 (21.21%)	45 (68.18%)	7 (10.61%)

CDSM – Driving Quality Improvement (Source NDSC)

The Red Rate Report shows how a specific provider's ordering scores rank in comparison to the average appropriateness by displaying a provider's normalized deviation from the population, typically within a provider specialty.

SNM

SOCIETY OF NUCLEAR MEDICINE

09/01/2015 to 05/01/2016 Details **Edit Filters** Provider Odds of Red Scored Exams **Red Count** Red Rate (unadjusted) Standard Error Provider 4636 9.9792 16 5 0.3125 0.5522 Provider 5096 9,4468 13 5 0.3846 0.5602 Provider 5289 9.3764 43 12 0.2791 0.3524 Provider 4951 8.5138 42 11 0.2619 0.3544 Provider 5393 23 6 0.2609 0.4832 7.8062 Provider 4882 7,7033 34 9 0.2647 0.3958 Provider 4593 3.3448 19 3 0.1579 0.6182 2 12 Provider 4438 3.3446 0.1667 0.7576 12 2 0.1667 Provider 5262 3.3329 0.7571 11 2 0.1818 0.7576 Provider 4181 3.3091 3 0.125 0.6148 Provider 4485 3.1828 24 Provider 4578 3.1551 20 3 0.15 0.6126 Provider 4729 3,1307 11 2 0.1818 0.7531 12 3 0.25 0.6262 Provider 4643 3.0786 Provider 5234 2.9764 18 3 0.1667 0.6302 Provider 4517 2.9437 29 3 0.1034 0.6025 Provider 5245 2.9247 11 2 0.1818 0.7449 14 2 0.1429 0.728 Provider 4913 2.8218 49

Red Rate Report

Medicare Physicians Fee Schedule Final Rule - 2018

S NM SOCIETY C

- In response to public comments, CMS is further delaying the effective date for the AUC consultation and reporting requirements to <u>January 1, 2020</u>.
- CMS is also finalizing a voluntary reporting period where early adopters can begin to report some consultation information on Medicare claims from July 2018 through December 2019.
- CMS notes that furnishing professionals are required to report the following information on Medicare claims for applicable imaging services:
 - Which qualified CDSM was consulted by the ordering professional
 - Whether the service ordered would adhere to specified applicable AUC, would not adhere to specified applicable AUC, or whether specified applicable AUC were not applicable to the service ordered
 - The NPI of the ordering professional (if different from the furnishing professional
- In response to the comments received, CMS decided not to move forward with the Gcode approach and will instead further explore and pursue the use of the unique consultation identifier for reporting on Medicare claims.



MACRA – Quality Payment Program







MACRA – Quality Payment Program


- Medicare and CHIP Reauthorization Act (MACRA)
- Signed into law April 2015
- Supports transition from fee-for-service payments to payments based on quality and value
- Established the Quality Payment Program (QPP)



The Quality Payment Program

The Quality Payment Program policy will:

- Reform Medicare Part B payments for more than 600,000 clinicians
- Improve care across the entire health care delivery system




Clinicians have two tracks to choose from:

What is Merit-based Incentive Payment System (MIPS)

SNM SOCIETY OF NUCLEAR MEDICINE

ND MOLECULAR IMAGING






What is Merit-based Incentive Payment System (MIPS)

SNM SOCIETY OF

MOLECULAR IMAGING

A visualization of how the legacy programs streamline into the MIPS performance categories:





The Quality Payment Program

No change in the types of clinicians eligible to participate in 2018



For 2019 onwards performance years:

Physical and occupational therapists, audiologists, nurse clinical social workers, clinical psychologists, and dietitians

midwives,



The Quality Payment Program

Change to the Low-Volume Threshold for 2018. <u>Include</u> MIPS eligible clinicians billing more than <u>\$90,000</u> a year in Medicare Part B allowed charges **AND** providing care for more than <u>200</u> Medicare patients a year.



Voluntary reporting remains an option for those clinicians who are exempt from MIPS.



MIPS – Non Patient Facing Criteria

No Change in Non-Patient Facing Criteria

Transition Year 1 (2017) Final

- Individual If you have <a href="mailto:
 <a href="mailto:how and base of the second secon
- Groups If your group has >75% of NPIs billing under your group's TIN during a performance period are labeled as non-patient facing.



۰

Year 2 (2018) Final

- No Change to Individual and Group policy.
- **NEW Virtual Groups** are included in the definition.
 - Virtual Groups that have >75% of NPIs within a virtual group during a performance period are labeled as non-patient facing



Performance Category Weights

MIPS Performance Categories for Year 2 (2018)



Comprised of four performance categories in 2018.

MIPS Performance Threshold and Payment Adjustment

Transition Year 1 (2017) Final

SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

SNM

Final Score 2017	Payment Adjustment 2019
<u>></u> 70 points	 Positive adjustment Eligible for exceptional performance bonus— minimum of additional 0.5%
4-69 points	 Positive adjustment Not eligible for exceptional performance bonus
3 points	Neutral payment adjustment
0 points	 Negative payment adjustment of -4% 0 points = does not participate

Year 2 (2018) Final

Final Score 2018	Change Y/N	Payment Adjustment 2020
≥70 points	N	 Positive adjustment greater than 0% Eligible for exceptional performance bonus— minimum of additional 0.5%
15.01- 69.99 points	Y	 Positive adjustment greater than 0% Not eligible for exceptional performance bonus
15 points	Y	Neutral payment adjustment
3.76- 14.99	Y	 Negative payment adjustment greater than -5% and less than 0%
0-3.75 points	Y	Negative payment adjustment of -5%



Reporting Options



1. Individual—under an National Provider Identifier (NPI) number and Taxpayer Identification Number (TIN) where they reassign benefits 2. As a Group

 a) 2 or more clinicians (NPIs) who have reassigned their billing rights to a single TIN*

b) As an APM Entity

As a Virtual Group – made up of solo practitioners and groups of 10 or fewer eligible clinicians who come together "virtually" (no matter what specialty or location) to participate in MIPS for a performance period for a year

3.

* If clinicians participate as a group, they are assessed as a group across all 4 MIPS performance categories. The same is true for clinicians participating as a Virtual Group.

MIPS Timeline



2018 Performance Year

AND MOLECULAR IMAGING

- Performance period opens January 1, 2018.
- Closes December 31, 2018.
- Clinicians care for patients and record data during the year.

March 31, 2019 Data Submission

- Deadline for submitting data is March 31, 2019.
- Clinicians are encouraged to submit data early.

Feedback

- CMS provides performance feedback after the data is submitted.
- Clinicians will receive feedback before the start of the payment year.

January 1, 2020 Payment Adjustment

 MIPS payment adjustments are prospectively applied to each claim beginning January 1, 2020.



Updates on AHCA, BCRA and ACA

- H.R.1628 American Health Care Act of 2017 Passed the house in May 2017, Senate didn't take it.
- U.S. Senate Committee on Budget released Better Care Reconciliation Act (BCRA) in June 2017 – Did not pass the Senate.
- Impact of Tax Reform Act 2017
 - Elimination of penalties paid by people who fail to have health insurance as required by the so-called individual mandate (could result in 13 million fewer American having health insurance)
 - Potential increases in average premiums as many young, healthy individuals will cease to carry health insurance leaving a sicker, more costly pool behind
 - Increase in the federal deficit by an estimated \$1.45 trillion
 - ACA employer mandate stays in place. Employers with 50 or more full time equivalent employees are required to file ACA information with IRS



"Known Unknowns" and "Unknown Unknowns"



"Known Unknowns"

- There are "known unknowns" and "unknowns and unknowns" for the future direction of CMS
- Legislative Landscape Very unlikely that any new healthcare legislation will be taken up before 2018 mid-terms
- Leadership at CMS and HHS Successful implementation of any program requires sustained buy in from the CMS leadership of successive administrations.
- New leadership at CMS and HHS

"Known Unknowns" – New CMS Administrator



SNM

UCLEAR MEDICINE

- New CMS Administration Seema Verma
- CMS non longer operating on the aggressive timeline to tie more Medicare payments to the quality of care received.
- Focus on review of alternative payment methods like "accountable care organization", "bundled payments" and "primary medical homes".
- "... I like to think of our initiative in terms of painting a house. Typically, repainting needs to occur every few years and before you repaint, you need to strip out the layers of paint from underneath... unfortunately, CMS has been applying new layers of paint without taking essential step."

"Known Unknowns" – New HHS Secretary




SNM

UCLEAR MEDICINE

- New HHS Secretary Alex Azar.
- Past President of Lilly USA, LLC, the largest division of Eli Lilly and Company.
- More interested in Medicare innovations than his predecessor Tom Price, who famously opposed the idea of requiring physicians to participate in any pilot programs.
- "… I totally agree about the need for value-based transformation. I think it's a bipartisan issue that we can improve quality, decrease cost and make our programs more sustainable." Alex Azar



"Unknown Unknowns"



- New Legislations?
- New Regulations?
- New Executive orders?
- More Personnel Changes?
- Something Totally Unexpected?

"If you don't know where you are going... any road will take you there"

Lewis Carroll

Thank you! Questions and Comments? <u>sahuja@snmmi.org</u>